Investor's Business Daily on MSN
Why Eli Lilly is the IBD stock of the day — again — as its Novo Nordisk rivalry deepens
Eli Lilly is Wednesday's IBD Stock Of The Day. Lilly shares are bounding off their 50-day line with a new buying opportunity ...
Investor's Business Daily on MSN
Exelixis earns IBD stock rating upgrade
The IBD SmartSelect Composite Rating for Exelixis rose from 94 to 96 Wednesday.
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...
Spyre Therapeutics, Inc. (NASDAQ:SYRE) is among the 14 best booming stocks to buy right now. On January 5, Wells Fargo reiterated a Buy rating on the stock, with a price target of $40. The update ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback